DMCC Speciality Chemicals Ltd

- The company is undertaking its largest-ever capex, with multiple projects extending up to December next year. - They plan to fund the capex using roughly a 2:1 debt-to-equity ratio. - Around ₹70 crore of loan is anticipated for this capex. - Interest rate on loans could be around 4-5% if converted to foreign currency loans; otherwise, 9-10% in Indian Rupees. - No specific mention of new equity fundraising; focus is on debt financing combined with equity. - The company emphasizes they are not extensively extending equity, aiming to maintain reasonable return on equity. - Management is confident about achieving planned cash flows from ongoing projects.

- Ongoing and upcoming capex includes expansion of specialty chemicals, intermediates for pharma and agrochemicals, and bulk chemicals. - Large investment at Dahej to create a second site similar in size to the Roha plant, including multipurpose and dedicated plants. - Capex includes a 50 crore investment in a sulphuric acid plant supporting both internal consumption (50%) and external sales (50%). - Additional investments include about 10 crore for two multipurpose plants (total), 20 crore in recently developed intermediate products, and debottlenecking to expand production at Roha. - The capex is the largest in the company's history, estimated to generate approximately 200 crore in revenue per 100 crore investment once plants run at full capacity. - Planned maintenance shutdown and restructuring have impacted recent operations; new investments signal a strategic growth phase. - Financing planned at a ~2:1 debt-to-equity ratio; options include foreign currency loans at 4-5% or INR loans at 9-10%. - Continued R&D investments for globally competitive processes and development of new products are ongoing.

- The company expects growth driven by expansion into specialty chemicals, including pharmaceuticals, agrochemicals, pigments, dyes, paints, and coatings sectors. - New and existing products, especially in specialty chemicals, are anticipated to scale up with increased traction, despite slower-than-expected initial growth due to COVID-related delays. - Domestic and overseas markets have returned to pre-COVID normalcy, with reasonable demand and operating revenues. - Planned debottlenecking at Roha will expand production of specialty products, adding to specialty revenue without drastically changing sulfuric acid sales. - Long-term demand for sulfones (thermal paper coatings) is expected to return once normal activities (stadiums, cinemas, airlines) resume. - Capex investments aim for roughly 2x revenue from new plants, with a mix of dedicated and multipurpose facilities. - New projects expected to be commercial and improve cash flows and return ratios fully by FY23, assuming no disruptions. - Overall, growth is driven by product expansion, capacity utilization, and targeted investments in higher-value specialty chemicals.

- Company expects growth driven by ramp-up of existing specialty chemical products and new dedicated plants. - Domestic and international markets showing signs of returning to pre-COVID levels, supporting revenue growth. - Expansion capex aimed at specialty intermediates and custom synthesis with planned investments at Roha and Dahej sites. - Anticipated 2x revenue generation from new intermediate projects with similar margin profiles as sulfones. - Bulk chemical margins expected to remain lower than specialty chemical margins; overall gross margins stable. - Growth in mature products expected if market normalcy continues. - No major new investments planned in bulk chemicals beyond current projects; focus on specialty chemicals. - Profitability may improve as new plants stabilize and optimize production. - External uncertainties remain (pandemic waves, commodity price fluctuations) which can impact near-term outlook.

The document does not explicitly mention the current or expected order book or pending orders for Dharamsi Morarji Chemical Company Limited. However, relevant insights inferred are: - The company has ongoing discussions and agreements with clients for dedicated specialty chemical plants, indicating confirmed orders or contracts. - There is reasonable confidence expressed by management in achieving planned cash flows from current projects based on customer discussions and existing supply. - The company continues investing in R&D and has products at various development stages, suggesting a pipeline but no quantified order backlog. - Demand from overseas and domestic markets is returning to pre-COVID levels, implying positive order inflow. - No precise figures or definite pending order backlog data are disclosed in the provided transcript.